Top Story
Signal 9/10
OpenAI Launches GPT-Rosalind: Specialized AI Model Tops Human Experts in Biology and Drug Discovery
OpenAI released GPT-Rosalind, its first model built for life sciences, excelling in drug discovery, protein analysis, and genetics by outperforming GPT-5.4 on key biology benchmarks and achieving above the 95th percentile of human experts on RNA prediction. Available as a research preview via trusted access, it's already partnering with Amgen, Moderna, and others to accelerate research. This marks OpenAI's rapid push into domain-specific frontier models.
Why it matters
Domain-specific models like GPT-Rosalind could compress 10-15 year drug development cycles, unlocking treatments for millions with rare diseases.